tetano
Editor, Senior Moderator
Diabetes Metab Syndr
. 2021 Oct 29;15(6):102326.
doi: 10.1016/j.dsx.2021.102326. Online ahead of print.
Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication
Uddalak Chakraborty[SUP] 1 [/SUP], Arkapravo Hati[SUP] 2 [/SUP], Atanu Chandra[SUP] 3 [/SUP]
Affiliations
Abstract
Background and aims: The COVID-19 pandemic has turned the world topsy turvy since its emergence and has claimed innumerable lives worldwide. Neurological manifestations of the disease have raised several eyebrows around the world among which Guillain-Barré syndrome (GBS) deserve special mention. Although majority of the cases of the coronavirus disease 2019 (COVID-19) present with respiratory symptoms, extrapulmonary manifestations are being increasingly reported. We conducted this study to analyze detailed clinical presentations and outcome in a series of eight cases (n = 8) with COVID-19 associated GBS.
Methods: An observational prospective study was conducted among patients with post-infectious/para-infectious GBS. 8 patients were subclassified into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) as per electrodiagnostic criteria and were followed up from admission to 6 months post discharge, to obtain a comprehensive clinical profile and outcome in these patients.
Results: The diagnosis of GBS was confirmed as per Asbury criteria, supported by electrodiagnostic features in nerve conduction velocity test. Among the series of 8 patients, 3 were diagnosed as AIDP, 3 had AMAN and the remaining 2 patients had AMSAN. 3 patients of GBS were afebrile and were diagnosed as COVID-19 after a positive assay on routine screening. Cerebro-spinal fluid analysis for SARS-Cov-2 RT-PCR and serum anti-ganglioside antibodies were negative in all the patients.
Conclusion: GBS in patients with COVID-19 should be differentiated from critical illness neuropathy and myopathy. Early diagnosis is important as it is associated with poor outcome and prolonged invasive ventilation.
Keywords: Acute inflammatory demyelinating polyradiculoneuropathy; Acute motor and sensory axonal neuropathy; Acute motor axonal neuropathy; COVID-19; Guillain-barré syndrome.
. 2021 Oct 29;15(6):102326.
doi: 10.1016/j.dsx.2021.102326. Online ahead of print.
Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication
Uddalak Chakraborty[SUP] 1 [/SUP], Arkapravo Hati[SUP] 2 [/SUP], Atanu Chandra[SUP] 3 [/SUP]
Affiliations
- PMID: 34731822
- DOI: 10.1016/j.dsx.2021.102326
Abstract
Background and aims: The COVID-19 pandemic has turned the world topsy turvy since its emergence and has claimed innumerable lives worldwide. Neurological manifestations of the disease have raised several eyebrows around the world among which Guillain-Barré syndrome (GBS) deserve special mention. Although majority of the cases of the coronavirus disease 2019 (COVID-19) present with respiratory symptoms, extrapulmonary manifestations are being increasingly reported. We conducted this study to analyze detailed clinical presentations and outcome in a series of eight cases (n = 8) with COVID-19 associated GBS.
Methods: An observational prospective study was conducted among patients with post-infectious/para-infectious GBS. 8 patients were subclassified into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) as per electrodiagnostic criteria and were followed up from admission to 6 months post discharge, to obtain a comprehensive clinical profile and outcome in these patients.
Results: The diagnosis of GBS was confirmed as per Asbury criteria, supported by electrodiagnostic features in nerve conduction velocity test. Among the series of 8 patients, 3 were diagnosed as AIDP, 3 had AMAN and the remaining 2 patients had AMSAN. 3 patients of GBS were afebrile and were diagnosed as COVID-19 after a positive assay on routine screening. Cerebro-spinal fluid analysis for SARS-Cov-2 RT-PCR and serum anti-ganglioside antibodies were negative in all the patients.
Conclusion: GBS in patients with COVID-19 should be differentiated from critical illness neuropathy and myopathy. Early diagnosis is important as it is associated with poor outcome and prolonged invasive ventilation.
Keywords: Acute inflammatory demyelinating polyradiculoneuropathy; Acute motor and sensory axonal neuropathy; Acute motor axonal neuropathy; COVID-19; Guillain-barré syndrome.